keyword
MENU ▼
Read by QxMD icon Read
search

Meningococcal vaccinations

keyword
https://www.readbyqxmd.com/read/29136861/quality-by-design-approach-in-the-development-of-an-ultra-high-performance-liquid-chromatography-method-for-bexsero-meningococcal-group-b-vaccine
#1
Luca Nompari, Serena Orlandini, Benedetta Pasquini, Cristiana Campa, Michele Rovini, Massimo Del Bubba, Sandra Furlanetto
Bexsero is the first approved vaccine for active immunization of individuals from 2 months of age and older to prevent invasive disease caused by Neisseria meningitidis serogroup B. The active components of the vaccine are Neisseria Heparin Binding Antigen, factor H binding protein, Neisseria adhesin A, produced in Escherichia coli cells by recombinant DNA technology, and Outer Membrane Vesicles (expressing Porin A and Porin B), produced by fermentation of Neisseria meningitidis strain NZ98/254. All the Bexsero active components are adsorbed on aluminum hydroxide and the unadsorbed antigens content is a product critical quality attribute...
February 1, 2018: Talanta
https://www.readbyqxmd.com/read/29132992/measuring-the-timeliness-of-childhood-vaccinations-using-cohort-data-and-routine-health-records-to-evaluate-quality-of-immunisation-services
#2
Suzanne Walton, Mario Cortina-Borja, Carol Dezateux, Lucy J Griffiths, Karen Tingay, Ashley Akbari, Amrita Bandyopadhyay, Ronan A Lyons, Helen Bedford
BACKGROUND: To achieve full benefits of vaccination programmes, high uptake and timely receipt of vaccinations are required. OBJECTIVES: To examine uptake and timeliness of infant and pre-school booster vaccines using cohort study data linked to health records. METHODS: We included 1782 children, born between 2000 and 2001, participating in the Millennium Cohort Study and resident in Wales, whose parents gave consent for linkage to National Community Child Health Database records at the age seven year contact...
November 10, 2017: Vaccine
https://www.readbyqxmd.com/read/29132919/clonal-replacement-and-expansion-among-invasive-meningococcal-isolates-of-serogroup-w-in-france
#3
Eva Hong, Anne-Sophie Barret, Aude Terrade, Mélanie Denizon, Denise Antona, Myriam Aouiti-Trabelsi, Ala-Eddine Deghmane, Isabelle Parent du Châtelet, Daniel Levy-Bruhl, Muhamed-Kheir Taha
Background Neisseria meningitidis group W (NmW) belonging to the clonal complex ST-11 (NmW/cc11) spread in Europe and in France in 2000 and declined thereafter. In France, invasive meningococcal disease (IMD) due to NmW increased again in 2012 and thereafter since 2015. Several sub-lineages of NmW/cc11 are circulating worldwide with successive epidemic waves. We aimed to describe recent epidemiological trends of NmW in France and to explore the microbiological and epidemiological characteristics associated with different NmW/cc11 sub-lineages...
November 10, 2017: Journal of Infection
https://www.readbyqxmd.com/read/29128379/active-sms-based-influenza-vaccine-safety-surveillance-in-australian-children
#4
Alexis Pillsbury, Helen Quinn, Patrick Cashman, Alan Leeb, Kristine Macartney
INTRODUCTION: Australia's novel, active surveillance system, AusVaxSafety, monitors the post-market safety of vaccines in near real time. We analysed cumulative surveillance data for children aged 6 months to 4 years who received seasonal influenza vaccine in 2015 and/or 2016 to determine: adverse event following immunisation (AEFI) rates by vaccine brand, age and concomitant vaccine administration. METHODS: Parent/carer reports of AEFI occurring within 3 days of their child receiving an influenza vaccine in sentinel immunisation clinics were solicited by Short Message Service (SMS) and/or email-based survey...
November 8, 2017: Vaccine
https://www.readbyqxmd.com/read/29126310/current-epidemiology-and-trends-in-meningococcal-disease-united-states-1996-2015
#5
Jessica R MacNeil, Amy E Blain, Xin Wang, Amanda C Cohn
Background: In 2005, meningococcal conjugate vaccine (MenACWY) was recommended for routine use among adolescents aged 11-18 years. This report describes the epidemiologic features of meningococcal disease and trends in meningococcal disease incidence following MenACWY introduction in the United States. Methods: Incidence rates and case-fatality ratios by age group and serogroup during 2006-2015 were calculated using data from the National Notifiable Diseases Surveillance System (NNDSS); changes in incidence during this time were evaluated...
November 8, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29116892/lessons-from-the-meningitis-vaccine-project
#6
F Marc LaForce, Mamoudou Djingarey, Simonetta Viviani, Marie-Pierre Preziosi
From 2001 to 2017 the Meningitis Vaccine Project (MVP), a Gates Foundation funded partnership between PATH and the World Health Organization (WHO), successfully developed, tested, licensed, and introduced an affordable new Group A meningococcal conjugate vaccine, MenAfriVac(®), in sub-Saharan Africa. The vaccine was well received, and from 2010 to 2016, over 260 million Africans have received a dose of the vaccine in campaigns largely directed at 1-29-year olds. The public health impact has been dramatic with the elimination of Group A meningococcal infections wherever the vaccine has been used at public health scale...
November 8, 2017: Viral Immunology
https://www.readbyqxmd.com/read/29114884/dental-provider-practices-and-perceptions-regarding-adolescent-vaccination
#7
Allison L Naleway, Michelle L Henninger, Lisa A Waiwaiole, David M Mosen, Michael C Leo, Daniel J Pihlstrom
OBJECTIVE: To assess dental providers' clinical practices and perceptions regarding adolescent vaccinations. METHODS: We surveyed 234 dental providers in an integrated health care setting in Portland, Oregon, in March-April 2015. We assessed participants' knowledge of adolescent vaccines, barriers to recommending vaccines, and their perceived role in the promotion of vaccination and preventive medical care. RESULTS: Over 80 percent of respondents correctly identified influenza, tetanus-diphtheria-acellular pertussis, and human papillomavirus as vaccinations recommended for adolescents; 60 percent correctly identified meningococcal conjugate...
November 8, 2017: Journal of Public Health Dentistry
https://www.readbyqxmd.com/read/29100708/safety-and-immune-response-after-two-dose-meningococcal-c-conjugate-immunization-in-hiv-infected-children-and-adolescents-in-rio-de-janeiro-brazil
#8
Ana Cristina C Frota, Bianca Ferreira, Lee H Harrison, Gisele S Pereira, Wania Pereira-Manfro, Elizabeth S Machado, Ricardo Hugo de Oliveira, Thalita F Abreu, Lucimar G Milagres, Cristina B Hofer
We aimed to evaluate immunogenicity and adverse events (AEs) after a booster dose of Meningococcal C conjugated (MCC) vaccine in HIV-infected children and adolescents, who had a previous low seroconversion rate after priming with MCC, at a reference HIV-care center in Rio de Janeiro. METHODS: 2-18 years old HIV-infected subjects with CD4+ T-lymphocyte cell (CD4) ≥15%, without active infection or antibiotic use, were enrolled to receive 2 doses of conjugated meningococcal C oligosaccharide-CRM197 12-18 months apart...
October 31, 2017: Vaccine
https://www.readbyqxmd.com/read/29095907/bacterial-meningitis-epidemiology-and-return-of-neisseria-meningitidis-serogroup-a-cases-in-burkina-faso-in-the-five-years-following-menafrivac-mass-vaccination-campaign
#9
Alpha Oumar Diallo, Heidi M Soeters, Issaka Yameogo, Guetawendé Sawadogo, Flavien Aké, Clément Lingani, Xin Wang, Andre Bita, Amadou Fall, Lassana Sangaré, Rasmata Ouédraogo-Traoré, Isaïe Medah, Brice Bicaba, Ryan T Novak
BACKGROUND: Historically, Neisseria meningitidis serogroup A (NmA) caused large meningitis epidemics in sub-Saharan Africa. In 2010, Burkina Faso became the first country to implement a national meningococcal serogroup A conjugate vaccine (MACV) campaign. We analyzed nationwide meningitis surveillance data from Burkina Faso for the 5 years following MACV introduction. METHODS: We examined Burkina Faso's aggregate reporting and national laboratory-confirmed case-based meningitis surveillance data from 2011-2015...
2017: PloS One
https://www.readbyqxmd.com/read/29094312/meningococcal-quadrivalent-tetanus-toxoid-conjugate-vaccine-menacwy-tt-nimenrix-%C3%A2-a-review
#10
Sohita Dhillon, David Pace
MenACWY-TT (Nimenrix(®)) is a quadrivalent meningococcal tetanus toxoid conjugate vaccine licensed in Europe for active immunisation of individuals aged ≥ 6 weeks against invasive disease caused by Neisseria meningitidis capsular groups A, C, W and Y. MenACWY-TT is the first quadrivalent conjugate vaccine to be approved in Europe for use in infants as young as 6 weeks of age. Numerous phase II-IIIb clinical studies showed that intramuscular MenACWY-TT administered as primary or booster vaccination was highly immunogenic for all four vaccine capsular groups and had an acceptable reactogenicity profile in individuals aged 6 weeks to ≥ 56 years...
November 2017: Drugs
https://www.readbyqxmd.com/read/29092704/epidemiology-of-invasive-meningococcal-b-disease-in-australia-1999-2015-priority-populations-for-vaccination
#11
Brett N Archer, Clayton K Chiu, Sanjay H Jayasinghe, Peter C Richmond, Jodie McVernon, Monica M Lahra, Ross M Andrews, Peter B McIntyre
OBJECTIVES: To describe trends in the age-specific incidence of serogroup B invasive meningococcal disease (IMD) in Australia, 1999-2015. DESIGN, SETTING, PARTICIPANTS: Analysis in February 2017 of de-identified notification data from the Australian National Notifiable Diseases Surveillance System of all notifications of IMD in Australia with a recorded diagnosis date during 1999-2015.Major outcomes: IMD notification rates in Australia, 1999-2015, by age, serogroup, Indigenous status, and region...
November 6, 2017: Medical Journal of Australia
https://www.readbyqxmd.com/read/29092703/trends-in-meningococcal-disease-challenges-for-vaccine-control-when-disease-is-rare
#12
Andrew J Pollard, Hannah Christensen
No abstract text is available yet for this article.
November 6, 2017: Medical Journal of Australia
https://www.readbyqxmd.com/read/29083344/invasive-meningococcal-disease-on-the-workplaces-a-systematic-review
#13
Matteo Riccò, Luigi Vezzosi, Anna Odone, Carlo Signorelli
Background and aims of the work: Invasive Meningococcal Disease (IMD) represents a global health threat, and occupational settings have the potential to contribute to its spreading. Therefore, here we present the available evidences on the epidemiology of IMD on the workplaces. METHODS: The following key words were used to explore PubMed: Neisseria meningitidis, meningococcus, meningococcal, invasive meningococcal disease, epidemiology, outbreaks, profession(al), occupation(al). RESULTS: We identified a total of 12 IMD cases among healthcare workers (HCW), 44 involving biological laboratory workers (BLW), 8 among school personnel, and eventually 27 from other settings, including 3 large industrial working populations...
October 23, 2017: Acta Bio-medica: Atenei Parmensis
https://www.readbyqxmd.com/read/29068749/combined-effect-of-pcv10-and-meningococcal-c-conjugate-vaccination-on-meningitis-mortality-among-children-under-five-years-of-age-in-brazil
#14
Ana Luiza Bierrenbach, Ruth Minamisava, Airlane Pereira Alencar, Gizelton Pereira Alencar, Ana Lucia Andrade
The 10-valent pneumococcal conjugate vaccine (PCV10) was introduced in the Brazilian National Immunization Program in March 2010, scheduled at 2, 4, and 6 months, with a booster at 12-15 months of age. The meningococcal C conjugate vaccine (MCC) was introduced in November 2010, scheduled at 3 and 5 months, with a booster dose at 12-15 months of age and no catch-up for older age groups. In this interrupted time-series analysis study, we used Brazilian mortality data from 2005 to 2015 for children under five years of age (excluding data from the state of Bahia) to assess the combined impact of these vaccines on the overall burden of meningitis mortality among children aged 0-23 months and 2-4 years, as defined using meningitis and meningococcemia specific International Classification of Diseases - tenth revision codes...
October 25, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/29066163/safety-and-efficacy-of-eculizumab-in-anti-acetylcholine-receptor-antibody-positive-refractory-generalised-myasthenia-gravis-regain-a-phase-3-randomised-double-blind-placebo-controlled-multicentre-study
#15
James F Howard, Kimiaki Utsugisawa, Michael Benatar, Hiroyuki Murai, Richard J Barohn, Isabel Illa, Saiju Jacob, John Vissing, Ted M Burns, John T Kissel, Srikanth Muppidi, Richard J Nowak, Fanny O'Brien, Jing-Jing Wang, Renato Mantegazza
BACKGROUND: Complement is likely to have a role in refractory generalised myasthenia gravis, but no approved therapies specifically target this system. Results from a phase 2 study suggested that eculizumab, a terminal complement inhibitor, produced clinically meaningful improvements in patients with anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis. We further assessed the efficacy and safety of eculizumab in this patient population in a phase 3 trial...
October 20, 2017: Lancet Neurology
https://www.readbyqxmd.com/read/29065137/differences-in-the-population-structure-of-neisseria-meningitidis-in-two-australian-states-victoria-and-western-australia
#16
Shakeel Mowlaboccus, Christopher A Mullally, Peter C Richmond, Benjamin P Howden, Kerrie Stevens, David J Speers, Anthony D Keil, Ottar N Bjørnstad, Timothy T Perkins, Charlene M Kahler
Neisseria meningitidis is the causative agent of invasive meningococcal disease (IMD). A recombinant vaccine called Bexsero® incorporates four subcapsular antigens (fHbp, NHBA, NadA and PorA) which are used to assign a Bexsero® antigen sequence type (BAST) to each meningococcal strain. The vaccine elicits an immune response against combinations of variants of these antigens which have been grouped into specific BAST profiles that have been shown to have different distributions within geographical locations thus potentially affecting the efficacy of the vaccine...
2017: PloS One
https://www.readbyqxmd.com/read/29064356/expansion-of-vaccination-services-and-strengthening-vaccine-preventable-diseases-surveillance-in-haiti-2010-2016
#17
Rania A Tohme, Jeannot Francois, Kathleen F Cavallaro, Gilson Paluku, Idrissa Yalcouye, Ernsley Jackson, Tracie Wright, Paul Adrien, Mark A Katz, Terri B Hyde, Pape Faye, Francine Kimanuka, Vance Dietz, John Vertefeuille, David Lowrance, Benjamin Dahl, Roopal Patel
Following the 2010 earthquake, Haiti was at heightened risk for vaccine-preventable diseases (VPDs) outbreaks due to the exacerbation of long-standing gaps in the vaccination program and subsequent risk of VPD importation from other countries. Therefore, partners supported the Haitian Ministry of Health and Population to improve vaccination services and VPD surveillance. During 2010-2016, three polio, measles, and rubella vaccination campaigns were implemented, achieving a coverage > 90% among children and maintaining Haiti free of those VPDs...
October 2017: American Journal of Tropical Medicine and Hygiene
https://www.readbyqxmd.com/read/29048988/developmental-strategy-for-a-new-group-a-meningococcalconjugate-vaccine-menafrivac-r
#18
Prasad S Kulkarni, Suresh S Jadhav, F Marc LaForce
Until recently, periodic Group A meningococcal meningitis outbreaks were a major public health problem in the sub-Saharan Africa. In 2001, the Meningitis Vaccine Project (MVP), a partnership between the World Health Organization (WHO) and PATH, a Seattle-based NGO, and the Serum Institute of India Pvt Ltd (SIIPL) initiated discussions aimed at establishing a collaborationto develop a Group A meningococcal conjugate vaccine for this unmet medical need. Over the next 8 years the partnership made countless strategic decisions about product characteristics, raw materials, potential target populations, geographic prioritization and affordability of the vaccine to name a few...
October 19, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/29048985/commentary-impact-of-meningococcal-group-b-omv-vaccines-beyond-their-brief
#19
Helen Petousis-Harris
Meningococcal group B outer membrane vesicle vaccines have been used widely in Cuba, New Zealand, and Brazil. They are immunogenic and initially assessed largely by their ability to induce serum bactericidal activity. Measures of efficacy indicate good protection against homologous strains in older children and adults. Effectiveness appears broader than predicted by immunogenicity and efficacy studies. The recent discovery that meningococcal group B OMVs may protect against the related Neisseria species N.gonorrhoeae suggests more to these interesting antigen collections than meets the eye...
October 19, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/29038320/persistence-of-immunity-after-vaccination-with-a-capsular-group-b-meningococcal-vaccine-in-3-different-toddler-schedules
#20
RANDOMIZED CONTROLLED TRIAL
Manish Sadarangani, Tim Sell, Mildred A Iro, Matthew D Snape, Merryn Voysey, Adam Finn, Paul T Heath, Gianni Bona, Susanna Esposito, Javier Diez-Domingo, Roman Prymula, Adefowope Odueyungbo, Daniela Toneatto, Andrew J Pollard
BACKGROUND: One schedule for the capsular group B meningococcal vaccine 4CMenB is 2 doses that are administered 2 months apart for children aged 12-23 months, with a booster dose 12-24 months later. Our objective was to provide data on persistence of human serum bactericidal antibody (hSBA) titres in children up to 4 years of age after initial doses at 12-24 months, and immunogenicity of a booster dose at 48 months of age compared with vaccine-naive children. METHODS: Children previously immunized, as part of a randomized controlled trial, with 2 doses of 4CMenB vaccine at 12-24 months of age received a booster at 4 years of age...
October 16, 2017: CMAJ: Canadian Medical Association Journal, Journal de L'Association Medicale Canadienne
keyword
keyword
106661
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"